PR Newswire
prCenter
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adultstranslating…
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- --…
Keywords#RSV#Positive Phase#Combination#PIV3#Adults
Comments
Sign in to join the discussion.
Loading comments…